Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

Introduction A non-interventional, multicenter, European, prospective evaluation of the effectiveness, tolerability, and safety of a topical preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in adults with open-angle glaucoma (OAG) and ocular...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2020-04, Vol.37 (4), p.1436-1451
Main Authors: Oddone, Francesco, Tanga, Lucia, Kóthy, Péter, Holló, Gábor
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Cardiology
Drug Combinations
Endocrinology
EUPAS
EUPAS22204
Female
Glaucoma, Open-Angle - drug therapy
Humans
Internal Medicine
Intraocular Pressure
Male
Medicine
Medicine & Public Health
Middle Aged
Ocular Hypertension - drug therapy
Oncology
Original Research
Pharmacology/Toxicology
Preservatives, Pharmaceutical
Prospective Studies
Prostaglandins F - administration & dosage
Prostaglandins F - adverse effects
Prostaglandins F - therapeutic use
Prostaglandins, Synthetic - administration & dosage
Prostaglandins, Synthetic - adverse effects
Prostaglandins, Synthetic - therapeutic use
Rheumatology
Timolol - administration & dosage
Timolol - adverse effects
Timolol - therapeutic use
Tonometry, Ocular
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction A non-interventional, multicenter, European, prospective evaluation of the effectiveness, tolerability, and safety of a topical preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in adults with open-angle glaucoma (OAG) and ocular hypertension (OHT) demonstrating insufficient response to topical beta-receptor blockers or prostaglandin analogue (PGA) monotherapy. Methods Mean intraocular pressure (IOP) change from baseline was measured at study visits following a switch to PF tafluprost/timolol FC. Primary endpoint was absolute mean IOP change at month 6. Change from baseline concerning ocular signs and symptoms was also explored. Results Analyses included 577 patients (59.6% female). Mean age (SD) was 67.8 (11.67) years. Mean (SD) IOP reduction from baseline was significant at all study visits; 5.4 (3.76) mmHg (23.7%) at week 4, 5.9 (3.90) mmHg (25.6%) at week 12, and 5.7 (4.11) mmHg (24.9%) at month 6 ( p  
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-020-01239-8